{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T23:15:50Z","timestamp":1785107750340,"version":"3.55.0"},"reference-count":130,"publisher":"Practical Medicine Publishing House","issue":"3","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Oncohematology"],"abstract":"<jats:p>Multiple myeloma (MM) is a malignancy characterized by bone marrow infiltration with plasma cell and extensive skeletal bone destruction resulting in bone pain and fractures. This review presents typical laboratory findings and clinical presentation of multiple myeloma.\u00a0Multiple myeloma is definite when the following hallmarks are present: \u00b3\u00a010% of clonal plasma cells in the bone marrow, M protein in serum or urine (except nonsecretory myeloma), hypercalcemia, renal insufficiency, anemia, or osteolytic lesions in skeletal bones. Monoclonal (M) proteins are detected using serum protein electrophoresis and immunofixation. In addition, urine protein electrophoresis and immunofixation or a serum free light-chain assay are essential.\u00a0The International Staging System classifies MM patients into three groups of risk\u00a0\u2014 standard, intermediate, or high\u00a0\u2014 depending on the b2-microglobulin and albumin serum levels. The presence of any one of the following indicates high-risk myeloma: a 13q deletion or hypodiploidy on metaphase cytogenetic studies, a 17p deletion, immunoglobulin heavy-chain translocations t(4;14) or t(14;16), or a plasma cell labeling index \u00b3\u00a03%.\r\nThis review presents laboratory findings and clinical manifestations of monoclonal gammopathy of undetermined significance, asymptomatic myeloma (\u2018smouldering myeloma\u2019), nonsecretory myeloma, solitary bone plasmacytoma, extramedullary plasmacytoma, plasma cell leukemia, Waldenstrom\u2019s macroglobulinemia, amyloidosis, and other diseases.<\/jats:p>","DOI":"10.21320\/2500-2139-2013-6-3-237-257","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T04:26:41Z","timestamp":1751344001000},"page":"237-257","source":"Crossref","is-referenced-by-count":13,"title":["Multiple myeloma (pathogenesis, clinical features, diagnosis, differential diagnosis). Part I","\u041c\u043d\u043e\u0436\u0435\u0441\u0442\u0432\u0435\u043d\u043d\u0430\u044f \u043c\u0438\u0435\u043b\u043e\u043c\u0430 (\u043f\u0430\u0442\u043e\u0433\u0435\u043d\u0435\u0437, \u043a\u043b\u0438\u043d\u0438\u043a\u0430, \u0434\u0438\u0430\u0433\u043d\u043e\u0441\u0442\u0438\u043a\u0430, \u0434\u0438\u0444\u0444\u0435\u0440\u0435\u043d\u0446\u0438\u0430\u043b\u044c\u043d\u044b\u0439 \u0434\u0438\u0430\u0433\u043d\u043e\u0437). \u0427\u0430\u0441\u0442\u044c I"],"prefix":"10.21320","volume":"6","author":[{"given":"S. S.","family":"Bessmeltsev","sequence":"first","affiliation":[{"name":"Russian Research Institute of Hematology and Transfusiology, Saint Petersburg, Russian Federation"},{"name":"\u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u0438\u0439 \u043d\u0430\u0443\u0447\u043d\u043e-\u0438\u0441\u0441\u043b\u0435\u0434\u043e\u0432\u0430\u0442\u0435\u043b\u044c\u0441\u043a\u0438\u0439 \u0438\u043d\u0441\u0442\u0438\u0442\u0443\u0442 \u0433\u0435\u043c\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u0438 \u0438 \u0442\u0440\u0430\u043d\u0441\u0444\u0443\u0437\u0438\u043e\u043b\u043e\u0433\u0438\u0438, \u0421\u0430\u043d\u043a\u0442-\u041f\u0435\u0442\u0435\u0440\u0431\u0443\u0440\u0433, \u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u0430\u044f \u0424\u0435\u0434\u0435\u0440\u0430\u0446\u0438\u044f"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8834","published-online":{"date-parts":[[2013,7,1]]},"reference":[{"key":"23835","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq178"},{"key":"23836","unstructured":"\u0411\u0435\u0441\u0441\u043c\u0435\u043b\u044c\u0446\u0435\u0432 \u0421.\u0421., \u0410\u0431\u0434\u0443\u043a\u0430\u0434\u044b\u0440\u043e\u0432 \u041a.\u041c. \u041c\u043d\u043e\u0436\u0435\u0441\u0442\u0432\u0435\u043d\u043d\u0430\u044f \u043c\u0438\u0435\u043b\u043e\u043c\u0430. \u0421\u043e\u0432\u0440\u0435\u043c\u0435\u043d\u043d\u044b\u0439 \u0432\u0437\u0433\u043b\u044f\u0434 \u043d\u0430 \u043f\u0440\u043e\u0431\u043b\u0435\u043c\u0443. \u0410\u043b\u043c\u0430\u0442\u044b, 2007. [Bessmeltsev S.S., Abdukadyrov K.M. Mnozhestvennaya miyeloma. Sovremennyy vzglyad na problemu (Multiple myeloma. Current view of the problem). Almaty, 2007.]"},{"key":"23837","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041875"},{"key":"23838","doi-asserted-by":"crossref","unstructured":"Fonseca R., Bergsagel P.L., Drach J. et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009; 23(12): 2210\u201321.","DOI":"10.1038\/leu.2009.174"},{"key":"23839","doi-asserted-by":"crossref","unstructured":"Anderson K.C. Targeted therapy for multiple myeloma. Hematol. 2001; 38: 286\u201394.","DOI":"10.1053\/shem.2001.26010"},{"key":"23840","doi-asserted-by":"publisher","DOI":"10.3109\/10428199209054904"},{"key":"23841","unstructured":"\u0425\u0430\u0440\u0447\u0435\u043d\u043a\u043e \u041c.\u0424., \u0411\u0435\u0441\u0441\u043c\u0435\u043b\u044c\u0446\u0435\u0432 \u0421.\u0421. \u0417\u043d\u0430\u0447\u0435\u043d\u0438\u0435 \u043f\u0440\u043e\u0442\u0435\u043e\u0433\u043b\u0438\u043a\u0430\u043d\u043e\u0432 \u0432 \u043f\u0430\u0442\u043e\u0433\u0435- \u043d\u0435\u0437\u0435 \u043c\u043d\u043e\u0436\u0435\u0441\u0442\u0432\u0435\u043d\u043d\u043e\u0439 \u043c\u0438\u0435\u043b\u043e\u043c\u044b. \u0411\u0438\u043e\u043c\u0435\u0434. \u0436\u0443\u0440\u043d. Medline.ru. 2010; 11: 404\u201323. [Kharchenko M.F., Bessmeltsev S.S. Znacheniye proteoglikanov v patogeneze mnozhestvennoy miyelomy (Significance of proteoglycans in pathogenesis of multiple myeloma. In: Biomed. journ.). Biomed. zhurn. Medline.ru. 2010; 11: 404\u201323.]"},{"key":"23842","doi-asserted-by":"publisher","DOI":"10.1042\/BST0340451"},{"key":"23843","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05299.x"},{"key":"23844","doi-asserted-by":"publisher","DOI":"10.1007\/BF02983377"},{"key":"23845","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1209699"},{"key":"23846","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-234757"},{"key":"23847","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.5.1658"},{"key":"23848","doi-asserted-by":"publisher","DOI":"10.3109\/10428190009060320"},{"key":"23849","unstructured":"Shain K., Landowski T., Dalton W.S. Cellular adhesion via Beta 1 integrins increases c-FLIPL levels and inhibits CD95\/Fas-mediated apoptosis in hematologic malignancies: A mechanism of immune evasion. 2001."},{"key":"23850","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2000.9r233.x"},{"key":"23851","doi-asserted-by":"publisher","DOI":"10.1053\/shem.2001.26010"},{"key":"23852","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.4.863.bloodjournal854863"},{"key":"23853","doi-asserted-by":"publisher","DOI":"10.1038\/nrc780"},{"key":"23854","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V73.4.865.bloodjournal734865"},{"key":"23855","doi-asserted-by":"crossref","unstructured":"Fonseca R., Oken M.H., Harrington D. et al. deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy. Leukemia 2001; 15: 981\u20136.","DOI":"10.1038\/sj.leu.2402125"},{"key":"23856","doi-asserted-by":"crossref","unstructured":"Fonseca R., Debes-Marun C.S., Picken E.B. et al. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood 2003; 102(7): 2562\u20137.","DOI":"10.1182\/blood-2003-02-0493"},{"key":"23857","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20998"},{"key":"23858","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.9.3025.421k53_3025_3034"},{"key":"23859","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.5726"},{"key":"23860","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200045"},{"key":"23861","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-02-0493"},{"key":"23862","unstructured":"Avet-Loiseau H., Facon T., Daviet A. et al. 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myelome. Cancer Res. 1999; 59: 4546\u201350."},{"key":"23863","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.1.217"},{"key":"23864","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2801"},{"key":"23865","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-12-261032"},{"key":"23866","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02546.x"},{"key":"23867","unstructured":"Bednarek A.K., Keck-Waggoner C.L., Daniel R.L. et al. WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res. 2001; 61: 8068\u201373."},{"key":"23868","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.97.1.228"},{"key":"23869","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.4.1505.h8001505_1505_1511"},{"key":"23870","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402125"},{"key":"23871","unstructured":"Boersma-Vreugdenhill G.R., Kuipers J., Bast B.J. Breakpoint analysis of a novel recurrent chromosomal translocation t(14;20)(q32;q12) in a human multiple myeloma cell line. VIIIth International Myeloma Workshop. Banff, Alberta, Canada, 2001: 124."},{"key":"23872","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.174"},{"key":"23873","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-279596"},{"key":"23874","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-009910"},{"key":"23875","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.7.2699.bloodjournal8872699"},{"key":"23876","unstructured":"Urashima M., Teoh G., Ogata A. et al. Characterization of p16(INK4A) expression in multiple myeloma and plasma cell leukemia. Cancer Res. 1997; 3: 2173\u20139."},{"key":"23877","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-299529"},{"key":"23878","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2005.01.017"},{"key":"23879","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi362"},{"key":"23880","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.5803"},{"key":"23881","unstructured":"Durie B.G., Waxman A.D., D\u2019Angolo A., Williams C.M. Whole-body FDG PET identifies high-risk myeloma. Nucl. Med. 2002; 43(11): 1457\u201363."},{"key":"23882","doi-asserted-by":"publisher","DOI":"10.1080\/10245330512331389782"},{"key":"23883","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.201394498"},{"key":"23884","unstructured":"Heider U., Langelotz C., Jakob C. et al. Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Cancer Res. 2003; 9: 1436\u201340."},{"key":"23885","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.7.2269"},{"key":"23886","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.6.2195.h81802002195_2195_2202"},{"key":"23887","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1687"},{"key":"23888","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030847"},{"key":"23889","unstructured":"\u0411\u0435\u0441\u0441\u043c\u0435\u043b\u044c\u0446\u0435\u0432 \u0421.\u0421., \u041a\u0430\u0440\u044f\u0433\u0438\u043d\u0430 \u0415.\u0412., \u0421\u0442\u0435\u043b\u044c\u043c\u0430\u0448\u0435\u043d\u043a\u043e \u041b.\u0412. \u0438 \u0434\u0440. \u0427\u0430\u0441\u0442\u043e\u0442\u0430, \u0445\u0430\u0440\u0430\u043a\u0442\u0435\u0440\u0438\u0441\u0442\u0438\u043a\u0430 \u0438 \u043c\u0435\u0442\u043e\u0434\u044b \u043b\u0435\u0447\u0435\u043d\u0438\u044f \u043f\u0435\u0440\u0438\u0444\u0435\u0440\u0438\u0447\u0435\u0441\u043a\u043e\u0439 \u043d\u0435\u0439\u0440\u043e\u043f\u0430\u0442\u0438\u0438 \u0443 \u0431\u043e\u043b\u044c\u043d\u044b\u0445 \u043c\u043d\u043e\u0436\u0435\u0441\u0442\u0432\u0435\u043d\u043d\u043e\u0439 \u043c\u0438\u0435\u043b\u043e\u043c\u043e\u0439, \u043f\u043e\u043b\u0443\u0447\u0430\u044e\u0449\u0438\u0445 \u0431\u043e\u0440\u0442\u0435\u0437\u043e\u043c\u0438\u0431 (\u0432\u0435\u043b\u043a\u0435\u0439\u0434). \u041e\u043d\u043a\u043e\u0433\u0435\u043c\u0430- \u0442\u043e\u043b\u043e\u0433\u0438\u044f 2008; 3: 52\u201362. [Bessmeltsev S.S., Karyagina Ye.V., Stelmashenko L.V. i dr. Chastota, kharakteristika i metody lecheniya perifericheskoy neyropatii u bolnykh mnozhestvennoy miyelomoy, poluchayushchikh bortezomib (velkeyd) (Incidence, characteristics, and methods of therapy for peripheral neuropathy in patients with multiple myeloma treated with bortezomib (Velcade). In: Oncohematology). Onkogematologiya 2008; 3: 52\u201362.]"},{"key":"23890","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.10003"},{"key":"23891","unstructured":"\u0420\u0443\u0433\u0430\u043b\u044c \u0412.\u0418., \u0411\u0435\u0441\u0441\u043c\u0435\u043b\u044c\u0446\u0435\u0432 \u0421.\u0421. \u041e\u0446\u0435\u043d\u043a\u0430 \u043e\u043f\u0443\u0445\u043e\u043b\u0435\u0432\u043e\u0439 \u0438\u043d\u0444\u0438\u043b\u044c\u0442\u0440\u0430\u0446\u0438\u0438 \u043a\u043e\u0441\u0442\u043d\u043e\u0433\u043e \u043c\u043e\u0437\u0433\u0430 \u043f\u0440\u0438 \u043c\u043d\u043e\u0436\u0435\u0441\u0442\u0432\u0435\u043d\u043d\u043e\u0439 \u043c\u0438\u0435\u043b\u043e\u043c\u0435 \u043f\u043e \u0440\u0435\u0437\u0443\u043b\u044c\u0442\u0430\u0442\u0430\u043c \u0438\u0441\u0441\u043b\u0435\u0434\u043e\u0432\u0430\u043d\u0438\u044f \u0442\u0440\u0435\u043f\u0430\u043d\u043e\u0431\u0438\u043e\u043f\u0442\u0430\u0442\u043e\u0432. \u0412\u0435\u0441\u0442\u043d. \u0433\u0435\u043c\u0430\u0442\u043e\u043b. 2009; 5(1): 49\u201350. [Rugal V.I., Bessmeltsev S.S. Otsenka opukholevoy infiltratsii kostnogo mozga pri mnozhestvennoy miyelome po rezultatam issledovaniya trepanobioptatov (Assessment of bone marrow tumor infiltration based on trephine biopsy findings. In: Hematol. bullet.). Vestn. gematol. 2009; 5(1): 49\u201350.]"},{"key":"23892","unstructured":"\u041b\u044e\u0434\u0432\u0438\u0433 \u0425., \u041e\u0441\u0442\u0435\u0440\u0431\u043e\u0440\u0433 \u0410. \u0410\u043d\u0435\u043c\u0438\u044f \u0438 \u0442\u0435\u0440\u0430\u043f\u0438\u044f \u044d\u0440\u0438\u0442\u0440\u043e\u043f\u043e\u044d\u0442\u0438\u043d\u043e\u043c \u043f\u0440\u0438 \u043c\u043d\u043e\u0436\u0435- \u0441\u0442\u0432\u0435\u043d\u043d\u043e\u0439 \u043c\u0438\u0435\u043b\u043e\u043c\u0435. \u0410\u043d\u0435\u043c\u0438\u044f \u0443 \u043e\u043d\u043a\u043e\u043b\u043e\u0433\u0438\u0447\u0435\u0441\u043a\u0438\u0445 \u0431\u043e\u043b\u044c\u043d\u044b\u0445. 2002; 1(\u0412\u044b\u043f. 1): 3\u201310. [Lyudvig Kh., Osterborg A. Anemiya i terapiya eritropoetinom pri mnozhestvennoy miyelome (Anemia and erythropoietin therapy in multiple myeloma. In: Anemia in cancer patients). Anemiya u onkologicheskikh bolnykh. 2002; 1(Vyp. 1): 3\u201310.]"},{"key":"23893","unstructured":"\u0411\u0435\u0441\u0441\u043c\u0435\u043b\u044c\u0446\u0435\u0432 \u0421.\u0421., \u0413\u0443\u0441\u0435\u0432\u0430 \u0421.\u0410. \u0421\u043e\u0432\u0440\u0435\u043c\u0435\u043d\u043d\u044b\u0435 \u043f\u0440\u0438\u043d\u0446\u0438\u043f\u044b \u043b\u0435\u0447\u0435\u043d\u0438\u044f \u0430\u043d\u0435\u043c\u0438\u0438 \u0443 \u043f\u0430\u0446\u0438\u0435\u043d\u0442\u043e\u0432 \u0441 \u043e\u043d\u043a\u043e\u0433\u0435\u043c\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u0447\u0435\u0441\u043a\u0438\u043c\u0438 \u0437\u0430\u0431\u043e\u043b\u0435\u0432\u0430\u043d\u0438\u044f\u043c\u0438. \u0423\u043a\u0440\u0430i\u043d. \u0436\u0443\u0440\u043d. \u0433\u0435\u043c\u0430\u0442\u043e\u043b. \u0442\u0430 \u0442\u0440\u0430\u043d\u0441\u0444\u0443\u0437i\u043e\u043b. 2009; 1: 5\u201317. [Bessmeltsev S.S., Guseva S.A. Sovremennye printsipy lecheniya anemii u patsientov s onkogematologicheskimi zabolevaniyami (Current principles of therapy for anemia in patients with hematological malignancies. In: Ukraine journal of hematol. & transfusiol.). Ukrain. zhurn. gematol. ta transfuziol. 2009; 1: 5\u201317.]"},{"key":"23894","doi-asserted-by":"publisher","DOI":"10.3109\/08860229609052784"},{"key":"23895","doi-asserted-by":"publisher","DOI":"10.1188\/11.CJON.S1.66-76"},{"key":"23896","unstructured":"\u0411\u0435\u0441\u0441\u043c\u0435\u043b\u044c\u0446\u0435\u0432 \u0421.\u0421. \u0411\u0438\u0441\u0444\u043e\u0441\u0444\u043e\u043d\u0430\u0442\u044b \u0438 \u0438\u0445 \u0440\u043e\u043b\u044c \u0432 \u043b\u0435\u0447\u0435\u043d\u0438\u0438 \u043c\u043d\u043e\u0436\u0435\u0441\u0442\u0432\u0435\u043d\u043d\u043e\u0439 \u043c\u0438\u0435\u043b\u043e\u043c\u044b. \u0423\u043a\u0440\u0430i\u043d. \u0436\u0443\u0440\u043d. \u0433\u0435\u043c\u0430\u0442\u043e\u043b. \u0442\u0430 \u0442\u0440\u0430\u043d\u0441\u0444\u0443\u0437i\u043e\u043b. 2011; 1: 5\u201318. [Bessmeltsev S.S. Bisfosfonaty i ikh rol v lechenii mnozhestvennoy miyelomy (Bisphosphonates and their role in therapy for multiple myeloma. In: Ukraine journ. of hematol. & transfusiol.). Ukrain. zhurn. gematol. ta transfuziol. 2011; 1: 5\u201318.]"},{"key":"23897","unstructured":"\u0427\u0443\u0431\u0443\u043a\u0438\u043d\u0430 \u0416.\u0412., \u0411\u0443\u0431\u043d\u043e\u0432\u0430 \u041b.\u041d., \u0411\u0435\u0441\u0441\u043c\u0435\u043b\u044c\u0446\u0435\u0432 \u0421.\u0421. \u0438 \u0434\u0440. \u041d\u0435\u0441\u043f\u0435\u0446\u0438\u0444\u0438\u0447\u0435\u0441\u043a\u0438\u0435 \u0444\u0430\u043a\u0442\u043e\u0440\u044b \u0437\u0430\u0449\u0438\u0442\u044b \u0438 \u0433\u0443\u043c\u043e\u0440\u0430\u043b\u044c\u043d\u044b\u0439 \u0438\u043c\u043c\u0443\u043d\u0438\u0442\u0435\u0442 \u0443 \u0431\u043e\u043b\u044c\u043d\u044b\u0445 \u043c\u043d\u043e\u0436\u0435\u0441\u0442\u0432\u0435\u043d\u043d\u043e\u0439 \u043c\u0438\u0435\u043b\u043e\u043c\u043e\u0439. \u041c\u0435\u0434. \u044d\u043a\u0441\u0442\u0440\u0435\u043c. \u0441\u0438\u0442\u0443\u0430\u0446\u0438\u0439 2012; 2: 93\u20138. [Chubukina Zh.V., Bubnova L.N., Bessmeltsev S.S. i dr. Nespetsificheskiye faktory zashchity i gumoralnyy immunitet u bolnykh mnozhestvennoy miyelomoy (Non-specific protective factors and humoral immunity in patients with multiple myeloma. In: Med. of extr. situations). Med. ekstrem. situatsiy 2012; 2: 93\u20138.]"},{"key":"23898","unstructured":"\u0411\u0435\u0441\u0441\u043c\u0435\u043b\u044c\u0446\u0435\u0432 \u0421.\u0421., \u0421\u0442\u0435\u043b\u044c\u043c\u0430\u0448\u0435\u043d\u043e \u041b.\u0412., \u0421\u0442\u0435\u043f\u0430\u043d\u043e\u0432\u0430 \u041d.\u0412. \u0438 \u0434\u0440. \u0411\u043e\u0440\u0442\u0435\u0437\u043e\u043c\u0438\u0431 (\u0432\u0435\u043b\u043a\u0435\u0439\u0434) \u0438 \u043c\u0435\u043b\u0444\u0430\u043b\u0430\u043d \u0441 \u043f\u0440\u0435\u0434\u043d\u0438\u0437\u043e\u043b\u043e\u043d\u043e\u043c \u0432 \u043b\u0435\u0447\u0435\u043d\u0438\u0438 \u043c\u043d\u043e\u0436\u0435\u0441\u0442\u0432\u0435\u043d\u043d\u043e\u0439 \u043c\u0438\u0435\u043b\u043e\u043c\u044b \u0443 \u043f\u043e\u0436\u0438\u043b\u044b\u0445 \u0431\u043e\u043b\u044c\u043d\u044b\u0445. \u041e\u043d\u043a\u043e\u0433\u0435\u043c\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u044f 2010; 2: 40\u20135. [Bessmeltsev S.S., Stelmasheno L.V., Stepanova N.V. i dr. Bortezomib (velkeyd) i melfalan s prednizolonom v lechenii mnozhestvennoy miyelomy u pozhilykh bolnykh (Bortezomib (Velcade) and melphalan combined with prednisolone in therapy for multiple myeloma in older patients. In: Oncohematology). Onkogematologiya 2010; 2: 40\u20135.]"},{"key":"23899","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-200194100-00021"},{"key":"23900","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.307"},{"key":"23901","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.11.2398"},{"key":"23902","doi-asserted-by":"publisher","DOI":"10.3816\/CLML.2010.n.078"},{"key":"23903","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-08-2436"},{"key":"23904","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U"},{"key":"23905","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.242"},{"key":"23906","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2011.02.008"},{"key":"23907","doi-asserted-by":"crossref","unstructured":"Kyle R.A., Rajkumar S.V. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23: 3\u20139.","DOI":"10.1038\/leu.2008.291"},{"key":"23908","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.61"},{"key":"23909","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-08-040410"},{"key":"23910","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.958.958"},{"key":"23911","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.15_suppl.8122"},{"key":"23912","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2009.0603"},{"key":"23913","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-10-3017"},{"key":"23914","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1411"},{"key":"23915","doi-asserted-by":"publisher","DOI":"10.4065\/82.3.323"},{"key":"23916","unstructured":"\u0411\u0435\u0441\u0441\u043c\u0435\u043b\u044c\u0446\u0435\u0432 \u0421.\u0421. \u0414\u0438\u0430\u0433\u043d\u043e\u0441\u0442\u0438\u043a\u0430 \u0438 \u0434\u0438\u0444\u0444\u0435\u0440\u0435\u043d\u0446\u0438\u0430\u043b\u044c\u043d\u0430\u044f \u0434\u0438\u0430\u0433\u043d\u043e\u0441\u0442\u0438\u043a\u0430 \u043c\u043d\u043e\u0436\u0435\u0441\u0442\u0432\u0435\u043d\u043d\u043e\u0439 \u043c\u0438\u0435\u043b\u043e\u043c\u044b. \u0412\u043e\u043f\u0440. \u043e\u043d\u043a\u043e\u043b. 2004; 4: 406\u201316. [Bessmeltsev S.S. Diagnostika i differentsialnaya diagnostika mnozhestvennoy miyelomy (Detection and differential diagnosis of multiple myeloma. In: Issues of oncol.). Vopr. onkol. 2004; 4: 406\u201316.]"},{"key":"23917","doi-asserted-by":"publisher","DOI":"10.5858\/1999-123-0114-SOTFMG"},{"key":"23918","doi-asserted-by":"crossref","unstructured":"Drayson M., Tang L.X., Drew R. et al. Serum free light chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001; 97(9): 2900\u20132.","DOI":"10.1182\/blood.V97.9.2900"},{"key":"23919","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-015784"},{"key":"23920","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-108357"},{"key":"23921","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/48.9.1437"},{"key":"23922","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05867.x"},{"key":"23923","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.291"},{"key":"23924","doi-asserted-by":"publisher","DOI":"10.4065\/81.5.693"},{"key":"23925","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.9.2900"},{"key":"23926","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1038"},{"key":"23927","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(05)70416-0"},{"key":"23928","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04355.x"},{"key":"23929","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198203113061002"},{"key":"23930","unstructured":"Diop P.A., Haudrechy D., Sylla-Niang M. et al. Laboratory diagnosis of monoclonal gammopathies. Prospective study of 14 cases in Dakar, Senegal. Bull. Soc. Pathol. 1998; 91: 242\u20136."},{"key":"23931","unstructured":"Sezer O., Heider U., Zavrski I., Possinger K. Differentiation of monoclonal gammopathy of undetermined significance and multiple myeloma using flow cytometric characteristics of plasma cells. Haematologica 2001; 86: 837\u201343."},{"key":"23932","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-7125(16)30734-9"},{"key":"23933","unstructured":"Weber D., Wang L.M., Delasalle K. et al. Risk factors for early progression of asymptomatic multiple myeloma. Hematology J. 2003; 4(Suppl. 1): S31."},{"key":"23934","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.6.1625"},{"key":"23935","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-192575"},{"key":"23936","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2010.0520"},{"key":"23937","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa01133202"},{"key":"23938","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-194241"},{"key":"23939","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-195008"},{"key":"23940","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070389"},{"key":"23941","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.7.1311"},{"key":"23942","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(00)01572-8"},{"key":"23943","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1983.1.4.255"},{"key":"23944","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990601)85:11<2305::AID-CNCR2>3.0.CO;2-3"},{"key":"23945","unstructured":"McKenna R.W., Kyle R.A., Kuehl W.M. et al. Plasma cell neoplasms. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Ed. by S.H. Swerdlow, E. Campo, N.L. Harris et al., 4th ed. Lyon: IARC Press, 2008: 200\u201313."},{"key":"23946","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(00)00102-8"},{"key":"23947","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-002-0480-5"},{"key":"23948","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2011.06.010"},{"key":"23949","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402116"},{"key":"23950","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.4"},{"key":"23951","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.06.027"},{"key":"23952","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-001-0420-9"},{"key":"23953","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2003.50082"},{"key":"23954","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.22014"},{"key":"23955","unstructured":"\u041a\u0440\u0438\u0432\u043e\u043b\u0430\u043f\u043e\u0432 \u042e.\u0410., \u041b\u0435\u0435\u043d\u043c\u0430\u043d \u0415.\u0415. \u041c\u043e\u0440\u0444\u043e\u043b\u043e\u0433\u0438\u0447\u0435\u0441\u043a\u0430\u044f \u0434\u0438\u0430\u0433\u043d\u043e\u0441\u0442\u0438\u043a\u0430 \u043b\u0438\u043c\u0444\u043e\u043c. \u0421\u041f\u0431.: \u0418\u0437\u0434\u0430\u0442\u0435\u043b\u044c\u0441\u043a\u043e-\u043f\u043e\u043b\u0438\u0433\u0440\u0430\u0444\u0438\u0447\u0435\u0441\u043a\u0430\u044f \u043a\u043e\u043c\u043f\u0430\u043d\u0438\u044f \u00ab\u041a\u043e\u0441\u0442\u0430\u00bb, 2006."},{"key":"23956","unstructured":"Krivolapov Yu.A., Leyenman Ye.Ye. Morfologicheskaya diagnostika limfom (Morphologic diagnosis of lymphomas). Spb.: Izdatelskopoligraficheskaya kompaniya \u00abKosta\u00bb, 2006."},{"key":"23957","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2003.50038"},{"key":"23958","unstructured":"\u041c\u0438\u0445\u0430\u0439\u043b\u043e\u0432 \u0410.\u041c., \u0411\u0435\u0441\u0441\u043c\u0435\u043b\u044c\u0446\u0435\u0432 \u0421.\u0421., \u041f\u043e\u0436\u0430\u0440\u0438\u0441\u0441\u043a\u0438\u0439 \u041a.\u041c. \u0438 \u0434\u0440. \u0411\u043e\u043b\u0435\u0437\u043d\u044c \u041a\u0430\u0441\u0442\u043b\u0435\u043c\u0430\u043d\u0430 \u0438 POEMS-\u0441\u0438\u043d\u0434\u0440\u043e\u043c, \u0438\u0445 \u043f\u0440\u043e\u044f\u0432\u043b\u0435\u043d\u0438\u044f \u0438 \u0432\u0437\u0430\u0438\u043c\u043e\u0441\u0432\u044f\u0437\u044c. \u0412 \u043a\u043d.: \u0420\u0435\u0434\u043a\u0438\u0435 \u0433\u0435\u043c\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u0447\u0435\u0441\u043a\u0438\u0435 \u0431\u043e\u043b\u0435\u0437\u043d\u0438 \u0438 \u0441\u0438\u043d\u0434\u0440\u043e\u043c\u044b. \u041f\u043e\u0434 \u0440\u0435\u0434. \u041c.\u0410. \u0412\u043e\u043b\u043a\u043e\u0432\u043e\u0439. \u041c.: \u041f\u0440\u0430\u043a\u0442\u0438\u0447\u0435\u0441\u043a\u0430\u044f \u043c\u0435\u0434\u0438\u0446\u0438\u043d\u0430, 2011: 360\u201383. [Mikhaylov A.M., Bessmeltsev S.S., Pozharisskiy K.M. i dr. Bolezn Kastlemana i POEMS-sindrom, ikh proyavleniya i vzaimosvyaz. V kn.: Redkiye gematologicheskiye bolezni i sindromy. Pod red. M.A. Volkovoy (Castleman\u2019s disease and POEMS syndrome, their presentation and interrelations. In: Rare hematological disorders and syndromes. Ed. by M.A. Volkova). : Prakticheskaya meditsina, 2011: 360\u201383.]"},{"key":"23959","unstructured":"\u0410\u043b\u0435\u043a\u0441\u0435\u0435\u0432 \u0412.\u0412. \u0414\u0438\u0430\u0433\u043d\u043e\u0441\u0442\u0438\u043a\u0430 \u0438 \u043b\u0435\u0447\u0435\u043d\u0438\u0435 \u0431\u043e\u043b\u0435\u0439 \u0432 \u043f\u043e\u044f\u0441\u043d\u0438\u0446\u0435, \u0432\u044b\u0437\u0432\u0430\u043d\u043d\u044b\u0445 \u043a\u043e\u043c\u043f\u0440\u0435\u0441\u0441\u0438\u043e\u043d\u043d\u043e\u0439 \u0440\u0430\u0434\u0438\u043a\u0443\u043b\u043e\u043f\u0430\u0442\u0438\u0435\u0439. \u0421\u043f\u0440\u0430\u0432. \u043f\u043e\u043b\u0438\u043a\u043b\u0438\u043d. \u0432\u0440\u0430\u0447\u0430 2002; 4: 28\u201332. Alekseyev V.V. Diagnostika i lecheniye boley v poyasnitse, vyzvannykh kompressionnoy radikulopatiyey [Diagnosis and treatment of lower back pain caused by compression radiculopathy. In: Desk book of polycl. doctor]. Sprav. poliklin. vracha 2002; 4: 28\u201332."},{"key":"23960","unstructured":"\u0411\u0430\u043b\u0430\u0431\u043e\u043b\u043a\u0438\u043d \u041c.\u0418. \u042d\u043d\u0434\u043e\u043a\u0440\u0438\u043d\u043e\u043b\u043e\u0433\u0438\u044f. \u041c.: \u0423\u043d\u0438\u0432\u0435\u0440\u0441\u0443\u043c \u043f\u0430\u0431\u043b\u0438\u0448\u0438\u043d\u0433, 1998. [Balabolkin M.I. Endokrinologiya (Endocrinology). : Universum pablishing, 1998.]"},{"key":"23961","unstructured":"\u041a\u043e\u043b\u043e\u043d\u0434\u0430\u0435\u0432 \u0410.\u0424., \u0411\u0430\u043b\u0431\u0435\u0440\u043a\u0438\u043d \u0410.\u0424. \u0411\u043e\u043b\u0435\u0437\u043d\u044c \u041f\u0435\u0434\u0436\u0435\u0442\u0430 (\u0434\u0435\u0444\u043e\u0440\u043c\u0438\u0440\u0443- \u044e\u0449\u0438\u0439 \u043e\u0441\u0442\u0438\u0442). \u0412\u0440\u0430\u0447 2003; 4: 13\u20136. [Kolondayev A.F., Balberkin A.F. Bolezn Pedzheta (deformiruyushchiy ostit) (Paget\u2019s disease (osteitis deformans). In: Medical practitioner). Vrach 2003; 4: 13\u20136.]"},{"key":"23962","unstructured":"\u0412\u0430\u0441\u0438\u043b\u044c\u0435\u0432 \u042e.\u0412. \u0411\u043e\u043b\u044c \u0437\u0430 \u0433\u0440\u0443\u0434\u0438\u043d\u043e\u0439: \u0434\u0438\u0444\u0444\u0435\u0440\u0435\u043d\u0446\u0438\u0430\u043b\u044c\u043d\u0430\u044f \u0434\u0438\u0430\u0433\u043d\u043e\u0441\u0442\u0438\u043a\u0430 \u0438 \u043b\u0435\u0447\u0435\u043d\u0438\u0435. Consilium medicum (\u041f\u0440\u0438\u043b\u043e\u0436\u0435\u043d\u0438\u0435). 2002; 3: 3\u20135. [Vasilyev Yu.V. Bol za grudinoy: differentsialnaya diagnostika i lecheniye (Retrosternal pain, differential diagnosis and treatment. In: Consilium medicum (Addendum)). Consilium medicum (Prilozheniye). 2002; 3: 3\u20135.]"},{"key":"23963","unstructured":"\u0411\u0435\u0441\u0441\u043c\u0435\u043b\u044c\u0446\u0435\u0432 \u0421.\u0421. \u041a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u0430\u044f \u0442\u0440\u0430\u043a\u0442\u043e\u0432\u043a\u0430 \u0443\u0432\u0435\u043b\u0438\u0447\u0435\u043d\u043d\u043e\u0439 \u0441\u043a\u043e\u0440\u043e\u0441\u0442\u0438 \u043e\u0441\u0435\u0434\u0430\u043d\u0438\u044f \u044d\u0440\u0438\u0442\u0440\u043e\u0446\u0438\u0442\u043e\u0432 \u043f\u0440\u0430\u043a\u0442\u0438\u043a\u0443\u044e\u0449\u0438\u043c \u0432\u0440\u0430\u0447\u043e\u043c (\u0427\u0430\u0441\u0442\u044c 1). \u0412\u0435\u0441\u0442\u043d. \u0433\u0435\u043c\u0430\u0442\u043e\u043b. 2005; 2: 54\u201362. [Bessmeltsev S.S. Klinicheskaya traktovka uvelichennoy skorosti osedaniya eritrotsitov praktikuyushchim vrachom (Chast 1) (Clinical interpretation of elevated erythrocyte sedimentation rate by medical practitioner (Part I). In: Hematol. bullet.). Vestn. gematol. 2005; 2: 54\u201362.]"},{"key":"23964","doi-asserted-by":"publisher","DOI":"10.1053\/ctrv.2000.0210"}],"container-title":["Clinical Oncohematology"],"original-title":[],"link":[{"URL":"https:\/\/bloodjournal.ru\/index.php\/coh\/article\/download\/667\/621","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bloodjournal.ru\/index.php\/coh\/article\/download\/667\/621","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T11:10:57Z","timestamp":1764501057000},"score":1,"resource":{"primary":{"URL":"https:\/\/bloodjournal.ru\/index.php\/coh\/article\/view\/667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,1]]},"references-count":130,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2013,7,1]]}},"URL":"https:\/\/doi.org\/10.21320\/2500-2139-2013-6-3-237-257","relation":{},"ISSN":["2500-2139","1997-6933"],"issn-type":[{"value":"2500-2139","type":"electronic"},{"value":"1997-6933","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7,1]]}}}